The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s biosimilar hormones market report forecasts the biosimilar hormones market size to grow to $7.68 Billion by 2027, with a CAGR (compound annual growth rate) of more than 26%.

Learn More On The Biosimilar Hormones Market Report 2023 – https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Biosimilar Hormones Market Size Forecast

The global biosimilar hormones market is expected to grow from $2.31 billion in 2022 to $3.03 billion in 2023 at a compound annual growth rate (CAGR) of 31.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar hormones market is expected to grow from $7.68 billion in 2027 at a CAGR of 26.2%.

Key Biosimilar Hormones Market Driver ­– Growth Need To Treat Patients With Prevailing Hormonal Deficiencies

For instance, in January 2022, according to the British Medical Journal, a UK-based peer-reviewed medical trade journal, the prevalence of GH deficiency (GHD) in children is thought to range from 1 in 3500 to 1 in 10000 across the globe. Also, in June 2022, according to a Medscape report, about 6,000 adults are expected to be diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market.

Request for A Sample Of The Global Biosimilar Hormones Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

Key Biosimilar Hormones Market Trend – Launching New Product

Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launches in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products in various locations to boost sales and maximise profits. For instance, in February 2022, Alvotech Holdings S.A., a Luxembourg-based biopharmaceutical company specialising in the development of biosimilar medicines, announced partnerships with Fuji Pharma Co. Ltd., a Japan based pharmaceutical company, to develop biosimilar drug candidates in Japan. Through this partnership, both companies have decided to add new elements to their strategic alliance for the creation and marketing of biosimilar medicines in Japan.

Biosimilar Hormones Market Segment

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types

2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications

3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/e-pharmacy, Specialty Clinics

Biosimilar Hormones Market Major Players and Strategies

Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma.

The Biosimilar Hormones Global Market Report 2023 covers regional data on biosimilar hormones market size, biosimilar hormones market trends and drivers, opportunities, strategies, and biosimilar hormones market competitor analysis. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Biosimilar hormones refer to the hormones included in the product that are chemically identical to those produced by your body. In fact, it’s possible that the hormones in bioidentical drugs are identical to those used in conventional hormone therapy. They are used to treat people whose hormone levels are low or out of whack.

View More Reports Related To The Biosimilar Hormones Market –

Biosimilar Growth Hormones Global Market Report 2023

Parathyroid Hormone Global Market Report 2023

Biosimilars Global Market Report 2023

Email us at [email protected]

Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Follow us on:

LinkedIn: https://bit.ly/3WzV8lZ

YouTube: https://bit.ly/3jiemhz

Global Market Model: https://bit.ly/3Was30B